Actinium Pharmaceuticals (Delaware) (ATNM) vs NextCure (NXTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NextCure (NXTC) has outperformed Actinium Pharmaceuticals (Delaware) (ATNM) over the past year, losing 1.0% versus a loss of 29.9%. Over five years, ATNM leads with a -86.6% price change compared with -93.5% for NXTC. Actinium Pharmaceuticals (Delaware) is the larger company by market cap ($34.0 million vs $31.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATNM | NXTC |
|---|---|---|
| Share price | $1.08 | $6.79 |
| Market cap | $33.96M | $31.08M |
| 1-day change | 0.00% | +0.15% |
| YTD return | -20.59% | -52.22% |
| 1-year return | -29.87% | -1.02% |
| 5-year return | -86.57% | -93.53% |
| P/E ratio (TTM) | 3.00 | — |
| EPS (TTM) | $0.36 | $-8.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.74 | $15.74 |
| 52-week low | $0.735 | $1.55 |
| Distance from 52-week high | -37.93% | -56.86% |
| Analyst consensus | none | none |
| Avg. price target upside | +233.33% | +194.55% |
| Average volume | 139.78K | 2.11M |
| Shares outstanding | 31.44M | 4.58M |
| Employees | 27 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NXTC has outperformed ATNM by 28.8 percentage points over the past year.
About Actinium Pharmaceuticals (Delaware)
ATNM stock →Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About NextCure
NXTC stock →NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
ATNM vs NXTC FAQ
Which is bigger, Actinium Pharmaceuticals (Delaware) or NextCure?
Actinium Pharmaceuticals (Delaware) (ATNM) is larger, with a market capitalization of $33.96M compared with $31.08M for NextCure (NXTC).
Which stock has performed better over the past year, ATNM or NXTC?
NXTC returned -1.02% over the past 12 months, compared with -29.87% for ATNM (price return, excluding dividends). Past performance does not predict future results.
Are Actinium Pharmaceuticals (Delaware) and NextCure in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.